Mallinckrodt Medical, Inc.

Mallinckrodt, Inc.

Other

University of Missouri

Mallinckrodt Chemical Works

Robert G Wolfangel

Edward A Deutsch

David H White

Dennis L Nosco

Steven R Woulfe

William H Ralston

Karen F Deutsch

Janet B Wilking

William P Cacheris

Linda Meeh

Gary J Ehrhardt

Howard A Anderson

Treated apatite particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the above-described apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for medical diagnostic imaging

Treated apatite particles are disclosed for enhancing radical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the abovedescribed apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for ultrasound imaging

Treated calcium/oxyanion-containing particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging ('MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, or tissue disease states is obtained. Depending on the diagnostic imaging technique, calcium/oxyanion-containing particles are treated to be paramagnetic, radiopaque, or echogenic. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the above-described particles and then performing the medical diagnostic procedure.

Treated calcium/oxyanion-containing particles for medical diagnostic

Treated apatite particles are disclosed for enhancing medical diagnostic imaging such as magnetic resonance imaging ('MRI'), magnetic resonance spectroscopy ('MRS'), magnetic resonance spectroscopy imaging (37 MRSI'), X-ray diagnostic imaging, and ultrasound imaging. Novel coating and manufacturing techniques are disclosed to control particle size and particle aggregation resulting in compositions for organ specific imaging of the liver, spleen, gastrointestinal tract, or tissue disease states is obtained. Depending on the diagnostic imaging technique, apatite particles are treated to be paramagnetic, radiopaque, or echogenic. The apatite particles may also be fluorinated to form stable fluoroapatite compositions useful for .sup.19 F imaging. Also disclosed are diagnostic compositions and methods of performing medical diagnostic procedures which involve administering to a warm-blooded animal a diagnostically effective amount of the abovedescribed apatite particles and then performing the medical diagnostic procedure.

Treated apatite particles for x-ray diagnostic imaging

Process for preparing a radionuclide generator for producing Tc-99m or Re-188. A clear solution containing a metallic cation and an anion comprising W-188 or Mo-99 is provided. The metallic cation is present in the solution as a dissolved complex of the metallic cation and a complexing agent and/or the anion being present in the solution as a dissolved complex of the anion and a complexing agent. The dissolved complex(es) are decomposed to form a slurry containing a precipitate of the metallic cation and the anion. The precipitate is transferred to an elutable container of a radionuclide generator.

Process for the preparation of rhenium-188 and technetium-99m generators

Preparation of apatite particles for medical diagnostic imaging

A method of preparing a stable, therapeutic radiopharmaceutical composition comprised of an alpha- or beta-emitting radionuclide and a ligand by lyophilizing a solution of the complex. The radionuclide preferably has a half-life of at least twelve hours. The invention also is directed to stable lyophilized radiopharmaceutical compositions prepared by this method. The invention is particularly suited to the preparation of radionuclide-labeled antibodies in a stable form which merely requires reconstitution at the point of use.

Stabilized therapeutic radiopharmaceutical complexes

Improved stannous pyrophosphate technetium-99m compositions.

Stannous pyrophosphate technetium-99m compositions

An improved process for lyophilizing pharmaceutical products capable of being labelled with a radionuclide.

Colloidal compositions with protective agents suitable for radioactive

Metal hydroxides such as Fe(OH).sub.2, Fe(OH).sub.3 and Sn(OH).sub.2 are prepared in the form of spherical particles of uniform and controlled size suitable for tagging with a radioactive element such as technetium-99m. Aqueous suspensions of such tagged particles are useful in scintigraphy as lung scanning agents.

Metal hydroxide scintigraphic agents and method of preparation

Dispersions useful in preparing radiopharmaceutical scanning agents.

Growing community of inventors

Ballwin, MO, United States of America

Robert G Wolfangel